ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.

Authors: Jiujie Cui, Wei Li, Jingyu Cao, Yingzhi Lu, Ming Quan, Jun Wu, Mei Zhang, Da Li, Xiujuan Qu, Zhiwei Li, Liwei Wang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4228

Source: Full article


Abstract

TPS4228